The open-label, two-stage, phase II study BASALT-1 (NCT01820325) evaluated the efficacy of the pan-PI3K inhibitor BKM120 in patients with recurrent NSCLC and PI3K pathway activation (Novartis Pharmaceuticals, 2013b). This evidence concerns the gene PIK3CB and non-small cell lung carcinoma.